Myriad Genetics Stock Price Prediction

MYGN Stock  USD 15.12  0.18  1.18%   
The relative strength index (RSI) of Myriad Genetics' share price is below 30 as of today. This indicates that the stock is becoming oversold or undervalued. The main point of the Relative Strength Index (RSI) is to track how fast people are buying or selling Myriad Genetics, making its price go up or down.

Oversold Vs Overbought

21

 
Oversold
 
Overbought
The successful prediction of Myriad Genetics' future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Myriad Genetics, which may create opportunities for some arbitrage if properly timed.
Using Myriad Genetics hype-based prediction, you can estimate the value of Myriad Genetics from the perspective of Myriad Genetics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Myriad Genetics to buy its stock at a price that has no basis in reality. In that case, they are not buying Myriad because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Myriad Genetics after-hype prediction price

    
  USD 15.12  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Myriad Genetics Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.
Intrinsic
Valuation
LowRealHigh
10.2913.7617.23
Details
Naive
Forecast
LowNextHigh
11.4114.8818.34
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
12.5218.3024.08
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Myriad Genetics. Your research has to be compared to or analyzed against Myriad Genetics' peers to derive any actionable benefits. When done correctly, Myriad Genetics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Myriad Genetics.

Myriad Genetics After-Hype Price Prediction Density Analysis

As far as predicting the price of Myriad Genetics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Myriad Genetics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Myriad Genetics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Myriad Genetics Estimiated After-Hype Price Volatility

In the context of predicting Myriad Genetics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Myriad Genetics' historical news coverage. Myriad Genetics' after-hype downside and upside margins for the prediction period are 11.65 and 18.59, respectively. We have considered Myriad Genetics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
15.12
15.12
After-hype Price
18.59
Upside
Myriad Genetics is somewhat reliable at this time. Analysis and calculation of next after-hype price of Myriad Genetics is based on 3 months time horizon.

Myriad Genetics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Myriad Genetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Myriad Genetics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Myriad Genetics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.88 
3.47
 0.00  
  0.13 
0 Events / Month
8 Events / Month
Uncertain
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
15.12
15.12
0.00 
0.00  
Notes

Myriad Genetics Hype Timeline

Myriad Genetics is now traded for 15.12. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.13. Myriad is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is now at -0.88%. %. The volatility of related hype on Myriad Genetics is about 2294.21%, with the expected price after the next announcement by competition of 15.25. About 98.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.9. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Myriad Genetics has Price/Earnings To Growth (PEG) ratio of 1.4. The entity recorded a loss per share of 1.28. The firm had not issued any dividends in recent years. Myriad Genetics had 2:1 split on the 26th of March 2009. Given the investment horizon of 90 days the next forecasted press release will be uncertain.
Check out Myriad Genetics Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.

Myriad Genetics Related Hype Analysis

Having access to credible news sources related to Myriad Genetics' direct competition is more important than ever and may enhance your ability to predict Myriad Genetics' future price movements. Getting to know how Myriad Genetics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Myriad Genetics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
GHGuardant Health 0.03 9 per month 2.90  0.03  7.53 (5.16) 17.48 
CDNACaredx Inc 1.59 11 per month 0.00 (0.17) 4.05 (6.49) 24.22 
CSTLCastle Biosciences 0.00 0 per month 2.80 (0.02) 4.85 (4.38) 19.49 
SHCSotera Health Co 0.1 8 per month 0.00 (0.17) 3.45 (3.99) 11.98 
SYNHSyneos Health 0.00 0 per month 0.85  0  2.13 (1.42) 9.20 
NEOGNeogen 0.75 13 per month 0.00 (0.09) 4.11 (6.46) 11.75 
RDNTRadNet Inc(1.62)9 per month 1.84  0.1  3.77 (2.61) 22.33 
NTRANatera Inc 5.41 8 per month 2.27  0.13  4.30 (3.75) 25.26 
MEDPMedpace Holdings 0.00 0 per month 0.00 (0.08) 3.53 (7.23) 16.64 
PSNLPersonalis 0.00 0 per month 0.00 (0.13) 8.46 (9.47) 35.38 
QGENQiagen NV 0.00 0 per month 0.00 (0.16) 2.06 (1.95) 5.80 
OLKOlink Holding AB 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
ACRSAclaris Therapeutics 0.00 0 per month 2.83  0.22  15.47 (4.96) 66.90 
EXASEXACT Sciences(1.62)8 per month 0.00 (0.05) 6.01 (3.29) 33.31 
ILMNIllumina(1.53)10 per month 2.03 (0.02) 3.90 (2.69) 12.84 
TWSTTwist Bioscience Corp(0.69)10 per month 0.00 (0.03) 6.77 (6.21) 17.59 

Myriad Genetics Additional Predictive Modules

Most predictive techniques to examine Myriad price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Myriad using various technical indicators. When you analyze Myriad charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Myriad Genetics Predictive Indicators

The successful prediction of Myriad Genetics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Myriad Genetics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Myriad Genetics based on analysis of Myriad Genetics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Myriad Genetics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Myriad Genetics's related companies.

Story Coverage note for Myriad Genetics

The number of cover stories for Myriad Genetics depends on current market conditions and Myriad Genetics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Myriad Genetics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Myriad Genetics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Myriad Genetics Short Properties

Myriad Genetics' future price predictability will typically decrease when Myriad Genetics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Myriad Genetics often depends not only on the future outlook of the potential Myriad Genetics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Myriad Genetics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding89.9 M
When determining whether Myriad Genetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Myriad Genetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Myriad Genetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Myriad Genetics Stock:
Check out Myriad Genetics Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.